Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed CLL
NCT06762431Phase 2Recruiting
- Sponsor
- Vitebsk Regional Clinical Cancer Centre
- Start
- May 2024
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 arms), sponsored by Vitebsk Regional Clinical Cancer Centre. Primary endpoints: Adverse events incidence at 24 months and Safety and tolerability at 24 months. Started May 2024; status: recruiting.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06762431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762431.